[go: up one dir, main page]

HK1213782A1 - 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物 - Google Patents

在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物

Info

Publication number
HK1213782A1
HK1213782A1 HK16101786.8A HK16101786A HK1213782A1 HK 1213782 A1 HK1213782 A1 HK 1213782A1 HK 16101786 A HK16101786 A HK 16101786A HK 1213782 A1 HK1213782 A1 HK 1213782A1
Authority
HK
Hong Kong
Prior art keywords
diagnosis
treatment
pharmaceutical composition
monoclonal antibody
rheumatoid arthritis
Prior art date
Application number
HK16101786.8A
Other languages
English (en)
Inventor
‧蒙特羅卡西米洛
‧卡薩克帕拉達
‧瑪佐拉赫爾拉
‧阿隆索拉梅爾茲
‧佩雷斯羅德裡格斯
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of HK1213782A1 publication Critical patent/HK1213782A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16101786.8A 2006-12-26 2016-02-18 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物 HK1213782A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060250 2006-12-26

Publications (1)

Publication Number Publication Date
HK1213782A1 true HK1213782A1 (zh) 2016-07-15

Family

ID=39562112

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101786.8A HK1213782A1 (zh) 2006-12-26 2016-02-18 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物

Country Status (19)

Country Link
US (3) US20100092423A1 (zh)
EP (1) EP2119452B1 (zh)
KR (1) KR101482956B1 (zh)
CN (2) CN101657215A (zh)
AR (1) AR064527A1 (zh)
AU (1) AU2007336563B2 (zh)
CA (1) CA2676185C (zh)
DK (1) DK2119452T3 (zh)
ES (1) ES2785043T3 (zh)
HK (1) HK1213782A1 (zh)
IT (1) ITTO20070942A1 (zh)
MY (1) MY165625A (zh)
NZ (1) NZ578635A (zh)
PE (1) PE20081553A1 (zh)
PL (1) PL2119452T3 (zh)
PT (1) PT2119452T (zh)
RU (1) RU2472526C2 (zh)
UY (1) UY30838A1 (zh)
WO (1) WO2008077355A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587632A (en) * 2008-03-14 2012-06-29 Biocon Ltd An anti-cd6 monoclonal antibody and a method thereof
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
US11062258B2 (en) 2012-02-24 2021-07-13 Netclearance Systems, Inc. Automated logistics management using proximity events
US11037196B2 (en) 2012-02-24 2021-06-15 Netclearance Systems, Inc. Interactive advertising using proximity events
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
AU2016232897B2 (en) * 2015-03-13 2021-05-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
CA3014079A1 (en) * 2016-02-10 2017-08-17 Cayman Chemical Company Incorporated Anti-citrullinated hla polypeptide antibodies and uses thereof
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
US11151534B2 (en) * 2016-11-29 2021-10-19 Netclearance Systems, Inc. Consumer interaction module for point-of-sale (POS) systems
US11334889B2 (en) 2016-11-29 2022-05-17 Netclearance Systems, Inc. Mobile ticketing based on proximity
CN109903854B (zh) * 2019-01-25 2023-04-07 电子科技大学 一种基于中医药文献的核心药物识别方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5723437A (en) * 1993-11-02 1998-03-03 Duke University CD6 ligand
US5423562A (en) * 1993-11-05 1995-06-13 Pearce, Jr.; Fredric C. Chair lift
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
GEP20012516B (en) * 1996-03-20 2001-08-27 Genentech Inc Tricyclic Compounds Having Activity Specific for Integring, Particularly , avB3 Integrins, Method for Preparation the Same as Drugs and Pharmaceutical Composition Containing Same
IL130864A0 (en) * 1997-03-03 2001-01-28 Bristol Myers Squibb Co Monoclonal antibodies to human cd6
NZ514914A (en) * 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
FI110553B (fi) * 2001-02-12 2003-02-14 Perlos Oyj Liitin ja liittimen irtopala
ES2192128B1 (es) * 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
KR20070072502A (ko) * 2004-09-29 2007-07-04 코와 가부시키가이샤 관절 류머티즘의 예방 및/또는 치료약
KR101019525B1 (ko) * 2004-11-12 2011-03-07 젠코어 인코포레이티드 ＦcRn에 대한 변경된 결합성을 갖는 Ｆc 변이체
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체

Also Published As

Publication number Publication date
CN101657215A (zh) 2010-02-24
PT2119452T (pt) 2020-05-08
WO2008077355A1 (es) 2008-07-03
EP2119452B1 (en) 2020-03-04
CN105251004A (zh) 2016-01-20
US20170066835A1 (en) 2017-03-09
RU2009128659A (ru) 2011-02-10
PL2119452T3 (pl) 2021-03-08
DK2119452T3 (da) 2020-04-20
NZ578635A (en) 2012-03-30
US20100092423A1 (en) 2010-04-15
AU2007336563B2 (en) 2012-11-01
KR101482956B1 (ko) 2015-01-15
ITTO20070942A1 (it) 2008-06-27
CA2676185C (en) 2013-03-12
CA2676185A1 (en) 2008-07-03
EP2119452A1 (en) 2009-11-18
KR20090122910A (ko) 2009-12-01
UY30838A1 (es) 2008-07-31
EP2119452A4 (en) 2012-06-06
MY165625A (en) 2018-04-18
ES2785043T3 (es) 2020-10-05
AU2007336563A1 (en) 2008-07-03
PE20081553A1 (es) 2008-12-10
US20160024220A1 (en) 2016-01-28
AR064527A1 (es) 2009-04-08
RU2472526C2 (ru) 2013-01-20

Similar Documents

Publication Publication Date Title
HK1213782A1 (zh) 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物
IL254157B (en) 3–14–eta antibodies and their uses for the diagnosis and treatment of arthritis
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
IL197831A0 (en) Human antibodies that bind cxcr4 and uses thereof
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP1998799B8 (en) Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
IL196550A0 (en) Anti-il-6 monoclonal antibodies and uses thereof
HK1199047A1 (zh) 單克隆抗體的可變區序列和使用方法
IL209277A0 (en) Human anti-il-6/il-6r antibodies, compositions comprising the same and uses thereof
EP2097534A4 (en) HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
EP1999148B8 (en) Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
IL191117A (en) Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor
IL193444A (en) Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
EP2023955A4 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
IL197148A (en) Antibodies and preparations for the treatment of antibodies caused by antibodies
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof